Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1249-1255

  Bressan, Alessandro ^a   Bigioni, Mario ^a   Bellarosa, Daniela ^a   Nardelli, Federica ^a   Irrissuto, Clelia ^a   Maggi, Carlo Alberto ^a   Binaschi, Monica ^a  

^a Menarini Ricerche ^*  (Italy)

Author keywords

Anthracycline sensitivity; HCT116 cells; HDAC inhibitor; Tumorigenic potential

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTHRACYCLINE DERIVATIVE; CYTOTOXIC AGENT; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 POLYPEPTIDE RELATED SEQUENCE A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 POLYPEPTIDE RELATED SEQUENCE B; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NATURAL KILLER CELL RECEPTOR NKG2D; SABARUBICIN; TSA; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL KILLING; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SENSITIVITY; ENGRAFTMENT; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INJECTION; INOCULATION; MEDIATOR; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; POLYMERASE CHAIN REACTION;

EID: 78149348772     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000979     Document Type: Article

References (31)

1. Lane AA and Chabner B: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
2. Owens J: 2006 drug approvals: finding the niche. Nat Rev Drug Discov 6: 99-101, 2007.
3. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.
4. Botrugno OA, Santoro F and Minucci S: Histone deacetylase inhibitors as a weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280: 134-144, 2009.
5. Bates SE and Piekartz RL: Histone deacetylase inhibitors in combinations: will preclinical promises be kept? Cancer J 13: 80-83, 2007.
6. UKCCCR Guidelines for the welfare of Animals in Experimental Neoplasia. Br J Cancer 1: 1-10, 1998.
7. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM and Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3: 1-88, 1972.
8. Friese MA, Platten M, Lutz SZ, et al: MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 63: 8996-9006, 2003.
9. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
10. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Abdeldaim AH, Torrico S and Bates SE: T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets and mechanisms of resistance. Blood 103: 4636-4643, 2004.
11. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T and Bates SE: Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide. Clin Cancer Res 12: 1547-1555, 2006.
12. Tabe Y, Konopleva M, Contractor R, Munsell M, Shober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J and Andreff M: Up-regulation of MDR1 and induction of resisitance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107: 1546-1554, 2006.
13. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA and Johnston RW: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003.
14. Fedier A, Dedes KJ, Imesch P, Von Buren AO and Fink D: The histone deactetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR-1 independent resistance in human colon cancer cells. Int J Oncol 31: 633-641, 2007.
15. Imesch P, Dedes KJ, Furlato M, Fink D and Fedier A: MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trihcostatin A in colon tumor cells. Int J Oncol 35: 631-640, 2009.
16. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005.
17. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A and Odum N: Cancer cells become suscetible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 1136-11145, 2005.
18. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberg A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, Wiktor-Jedrzejczak W, Kalberer CP and Wodnar-Filipowicz: A NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK cell lines with single KIR-HLA-class I specificities. Blood 111: 1428-1436, 2008.
19. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M and Imamura M: Regulation of the expression of MHC class I-related chain A,B (MICA, MICB) via chromatin remodelling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21: 2103-2108, 2007.
20. Johnson CA, Padget K, Austin CA and Turner BM: Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 276: 4539-4542, 2001.
21. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D and Seto E: Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26: 349-353, 2000.
22. Kim MS, Blake M, Back JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
23. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC and Kroll DJ: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1: 121-131, 2001.
24. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I and Phillips DR: Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61: 8194-8202, 2001.
25. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM and Münster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237, 2004.
26. Marchion DC, Bicaku E, Daud AI, Sullivan DM and Münster PN: In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4: 1993-2000, 2005.
27. Münster PN, Marchion DC, Bicaku E, Schmitt M, Lee JH, De Conti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan DM and Daud AI: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translation study. J Clin Oncol 25: 1879-1985, 2007.
28. Zyss D, Montcourrier P, Vidal B, Anguille C, Mérezègue F, Sahuquet A, Mangeat PH and Coopman PJ: The Syk tyrosine kinase localizes to the centrosomes and negatively effects mitotic progression. Cancer Res 65: 10872-10880, 2005.
29. Coopman PJ and Mueller SC: The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett 241: 159-173, 2006.
30. Wang L, Devarajan E, He J, Reddy SP and Dai JL: Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res 65: 10289-10297, 2005.
31. Yuan Y, Liu H, Sahin A and Dai JL: Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113: 654-659, 2005.